Skip to content

Contact +44 (0) 20 7060 7474 email us

Biotechnology

The Future of Monoclonal Antibodies

Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

Publication Date December 2009
Publisher GBI Research
Product Type Report
Pages 132
ISBN Number not applicable
Product Code GBI00004

Price

£2,310.00
approximately: $3,498 | €2,578

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

GBI Research, the leading business intelligence provider, has released its latest research "The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis." The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global monoclonal antibodies market. The report analyzes the markets for monoclonal antibodies in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, annual cost of therapy and market potential are forecast until 2015 for select segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of this report includes:

  • Annualized market data for the monoclonal antibodies market from 2000 to 2008, forecast forward to 2015
  • Analysis of the potential for the monoclonal antibodies market in select therapeutic areas. These include HER2 breast cancer, bone metastases, multiple sclerosis, Non Small Cell Lung cancer (NSCLC) and Rheumatoid Arthritis
  • Market characterization of the monoclonal antibodies market including market size, annual cost of therapy, sales volume and treatment usage patterns
  • Key drivers and barriers that have a significant impact on the market
  • Coverage of pipeline molecules in various phases of drug development
  • Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Abbott Laboratories, Johnson & Johnson, Merck & Co, Biogen Idec, AstraZeneca, Bristol -Myers Squibb, Elan Pharmaceuticals, Amgen Inc and Eli Lilly
  • Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global monoclonal antibodies market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

  • Align product portfolio to the markets with high growth potential
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
  • Develop key strategic initiatives by understanding key focus areas of leading companies
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Contents

  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Global Monoclonal Antibodies Market: Introduction
    • 2.1 GBI Research Report Guidance
  • 3 Global Monoclonal Antibodies Market: Market Characterization
    • 3.1 Introduction
    • 3.2 Revenue Forecasts for the Global MAbs Market Potential
      • 3.2.1 MAbs Treatment Potential
      • 3.2.2 Drug Prices
      • 3.2.3 Market Potential
      • 3.2.4 Market Potential Segmentation
    • 3.3 Revenue Forecasts of Global MAbs Market - Actual Market
      • 3.3.1 MAbs Actual Treatment Population
      • 3.3.2 Actual Sales
      • 3.3.3 Actual Sales Segmentation
    • 3.4 Treatment Usage Patterns
    • 3.5 Global MAbs Trends
      • 3.5.1 Market Trends
      • 3.5.2 Technology Trends
    • 3.6 Product Trends
      • 3.6.1 Research and Development Focus Shifted Towards Humanized and Fully Humanized MAbs
    • 3.7 Global MAbs Market Drivers
      • 3.7.1 Gradual Growth in the Uptake of MAbs Have Driven the Monoclonal Antibody Sales Growth
      • 3.7.2 Improved Side-effect Profiles and Tolerance of MAbs Therapy
      • 3.7.3 Lack of Effective Conventional Therapies Accelerates Utilization of MAbs
      • 3.7.4 Expanded Indications Opens up New Potential Patient Group
      • 3.7.5 Lack of Generics Augmented the Sales Growth of MAbs
    • 3.8 Global MAbs Market Restraints
      • 3.8.1 High Cost of MAbs Hampering the Growth of Treatment Population
      • 3.8.2 Adverse Effects - Generation of Antibodies against MAbs in Patients Receiving Monoclonal Antibody Therapy
      • 3.8.3 Industry Challenges - Majority of MAbs Receive Approvals as Last Option Therapies
    • 3.9 Unmet Needs
      • 3.9.1 The High Cost of MAb Therapies is the Major Unmet Need and it is Also Responsible for Low Utilization by Patients
      • 3.9.2 MAbs Do Not Cure the Disease; They either Treat Signs and Symptoms or Decelerate Cell Proliferation
  • 4 Global MAbs Market Potential: Therapeutic Distribution
    • 4.1 MAbs Market Potential in HER2 Breast Cancer (Adjuvant and Metastatic)
      • 4.1.1 Introduction
      • 4.1.2 Prescription Population
      • 4.1.3 Annual Cost of Therapy
      • 4.1.4 Market Potential
    • 4.2 MAbs Market Potential in Bone Metastases and Bone Loss Due to Cancer Therapy
      • 4.2.1 Introduction
      • 4.2.2 Prescription Population
      • 4.2.3 Annual Cost of Therapy
      • 4.2.4 Market Potential
    • 4.3 MAbs Market Potential in Relapsing-remitting Multiple Sclerosis (RRMS)
      • 4.3.1 Introduction
      • 4.3.2 Prescription Population
      • 4.3.3 Annual Cost of Therapy
      • 4.3.4 Market Potential
    • 4.4 MAbs Market Potential in Metastatic Non-Small Cell Lung Cancer (NSCLC)
      • 4.4.1 Introduction
      • 4.4.2 Prescription Population
      • 4.4.3 Annual Cost of Therapy
      • 4.4.4 Market Potential
    • 4.5 MAbs Market Potential in Rheumatoid Arthritis
      • 4.5.1 Introduction
      • 4.5.2 Prescription Population
      • 4.5.3 Annual Cost of Therapy
      • 4.5.4 Market Potential
  • 5 Global MAbs Market: Pipeline Analysis
    • 5.1 Introduction
    • 5.2 MAbs Nomenclature
    • 5.3 Monoclonal Antibody Technology
    • 5.4 Applications of MAbs
      • 5.4.1 Detection Assays
      • 5.4.2 Purification Techniques
      • 5.4.3 Gene Identification
      • 5.4.4 Applied Chemistry
      • 5.4.5 Disease Therapy
    • 5.5 Therapeutic Applications in Oncology
      • 5.5.1 Introduction
      • 5.5.2 Marketed Therapies
      • 5.5.3 Therapies in Late Stage Pipeline
    • 5.6 Therapeutic Applications in Autoimmune and Inflammatory Diseases
      • 5.6.1 Introduction
      • 5.6.2 Marketed Therapies
      • 5.6.3 Therapies in Late Stage Pipeline
    • 5.7 Therapeutic Applications in Respiratory Diseases
      • 5.7.1 Introduction
      • 5.7.2 Marketed Therapies
      • 5.7.3 Therapies in Late Stage Pipeline
    • 5.8 Therapeutic Applications in Infectious Diseases
      • 5.8.1 Introduction
      • 5.8.2 Marketed Therapies
      • 5.8.3 Therapies in Pipeline
    • 5.9 Therapeutic Applications in Organ Transplantation
      • 5.9.1 Introduction
      • 5.9.2 Marketed Therapies
    • 5.10 Therapeutic Applications in Cardiovascular Diseases
      • 5.10.1 Introduction
      • 5.10.2 Marketed Therapies
      • 5.10.3 Therapies in Pipeline
    • 5.11 New Indications
      • 5.11.1 Central Nervous System
      • 5.11.2 Diabetes
    • 5.12 Insights into Most Promising Drugs
      • 5.12.1 Denosumab
  • 6 Global MAbs Market: M&A Landscape
    • 6.1 Overview
      • 6.1.1 Emergent BioSolutions acquires Avanir Pharmaceuticals
      • 6.1.2 MacroGenics acquires Raven Biotechnologies
      • 6.1.3 Thermo Fisher acquires Affinity BioReagents
    • 6.2 R&D Licensing Agreements
      • 6.2.1 Deals by Phase
      • 6.2.2 Deals by Geography
      • 6.2.3 Deals by Licensing Type
      • 6.2.4 Deals by Value ($)
      • 6.2.5 Preclinical
      • 6.2.6 Phase I
      • 6.2.7 Phase II
      • 6.2.8 Phase III
      • 6.2.9 Approved
  • 7 Global MAbs Market: Competitive Landscape
    • 7.1 Evolving competitive landscape
      • 7.1.1 Major players
      • 7.1.2 Key MAbs in the Market
    • 7.2 Company Benchmarking Analysis
    • 7.3 Roche/Genentech
      • 7.3.1 Key Monoclonal Antibody Drugs
      • 7.3.2 Key Indications of Interest
      • 7.3.3 Pipeline Analysis
    • 7.4 Abbott
      • 7.4.1 Key MAbs
      • 7.4.2 Key Indications of Interests
      • 7.4.3 Pipeline Analysis
    • 7.5 Johnson & Johnson
      • 7.5.1 Key MAbs
      • 7.5.2 Key Indications of Interest
      • 7.5.3 Pipeline Analysis
    • 7.6 Biogen Idec
      • 7.6.1 Key MAbs
      • 7.6.2 Key Indications of Interest
      • 7.6.3 Pipeline Analysis
    • 7.7 Merck/Schering Plough
      • 7.7.1 Key MAbs
      • 7.7.2 Key Indications of Interest
      • 7.7.3 Pipeline Analysis
    • 7.8 AstraZeneca
      • 7.8.1 Key MAbs
      • 7.8.2 Key Indications of Interest
      • 7.8.3 Pipeline Analysis
    • 7.9 Bristol-Myers Squibb
      • 7.9.1 Key MAbs
      • 7.9.2 Key Indications of Interest
    • 7.10 Elan
      • 7.10.1 Key MAbs
      • 7.10.2 Key Indications of Interest
      • 7.10.3 Pipeline Analysis
    • 7.11 Eli Lilly
      • 7.11.1 Key Monoclonal Antibody Drugs
      • 7.11.2 Key Indications of Interests
      • 7.11.3 Pipeline Analysis
    • 7.12 Amgen
      • 7.12.1 Key Monoclonal Antibody Drugs
      • 7.12.2 Key Indications of Interest
      • 7.12.3 Pipeline Analysis
  • 8 Global MAbs Market: Appendix
    • 8.1 Research Methodology
    • 8.2 Geographical Scope
    • 8.3 Coverage
    • 8.4 Secondary Research
    • 8.5 Primary Research
    • 8.6 Forecasts
      • 8.6.1 Epidemiology-based Forecasting
    • 8.7 Expert Panel Validation
    • 8.8 Contact Us
    • 8.9 Disclaimer
  • 1.1 List of Tables
    • Table 1: MAbs Market, Global, MAbs Treatment Potential, 2000-2008
    • Table 2: MAbs Market, Global, MAbs Treatment Potential, 2008-2015
    • Table 3: MAbs Market, Global, Annual Cost of Therapy ($), 2000-2008
    • Table 4: MAbs Market, Global, Annual Cost of Therapy ($), 2008-2015
    • Table 5: MAbs Market, Global, MAbs Market Potential ($ bn), 2000-2008
    • Table 6: MAbs Market, Global, MAbs Market Potential ($ bn), 2008-2015
    • Table 7: MAbs Market, Global, MAbs Actual Treatment Population, 2000-2008
    • Table 8: MAbs Market, Global, MAbs Actual Treatment Population, 2008-2015
    • Table 9: MAbs Market, Global, Actual Sales ($ bn), 2000-2008
    • Table 10: MAbs Market, Global, Actual Sales ($ bn), 2008-2015
    • Table 11: MAbs Market, Global, Actual Sales Segmentation ($ bn), 2000-2008
    • Table 12: MAbs Market, Global, Actual Sales Segmentation ($ bn), 2008-2015
    • Table 13: MAbs Market, Global, HER2+ Breast Cancer, Prescription Population, 2000-2008
    • Table 14: MAbs Market, Global, HER2+ Breast Cancer, Prescription Population, 2008-2015
    • Table 15: MAbs Market, Global, HER2+ Breast Cancer, Annual Cost of Therapy ($), 2000-2008
    • Table 16: MAbs Market, Global, HER2+ Breast Cancer, Annual Cost of Therapy ($), 2008-2015
    • Table 17: MAbs Market, Global, HER2+ Breast Cancer, Market Potential ($ bn), 2000-2008
    • Table 18: MAbs Market, Global, HER2+ Breast Cancer, Market Potential ($ bn), 2008-2015
    • Table 19: MAbs Market, Global, Bone Metastasis and Bone Loss, Prescription Population, 2009-2015
    • Table 20: MAbs Market, Global, Bone Metastasis and Bone Loss, Annual Cost of Therapy ($), 2009-2015
    • Table 21: MAbs Market, Global, Bone Metastasis and Bone Loss, Market Potential ($ bn), 2009-2015
    • Table 22: MAbs Market, Global, RRMS, Treatment Options, 2008
    • Table 23: MAbs Market, Global, RRMS, Prescription Population, 2000-2008
    • Table 24: MAbs Market, Global, RRMS, Prescription Population, 2008-2015
    • Table 25: MAbs Market, Global, RRMS, Annual Cost of Therapy ($), 2000-2008
    • Table 26: MAbs Market, Global, RRMS, Annual Cost of Therapy ($), 2008-2015
    • Table 27: MAbs Market, Global, RRMS, Market Potential ($ bn), 2000-2008
    • Table 28: MAbs Market, Global, RRMS, Market Potential ($ bn), 2008-2015
    • Table 29: MAbs Market, Global, Metastatic NSCLC, Treatment Options, 2008
    • Table 30: MAbs Market, Global, Metastatic NSCLC, Prescription Population, 2000-2008
    • Table 31: MAbs Market, Global, Metastatic NSCLC, Prescription Population, 2008-2015
    • Table 32: MAbs Market, Global, Metastatic NSCLC, Annual Cost of Therapy ($), 2000-2008
    • Table 33: MAbs Market, Global, Metastatic NSCLC, Annual Cost of Therapy ($), 2008-2015
    • Table 34: MAbs Market, Global, Metastatic NSCLC, Market Potential ($ bn), 2000-2008
    • Table 35: MAbs Market, Global, Metastatic NSCLC, Market Potential ($ bn), 2008-2015
    • Table 36: MAbs Market, Global, Rheumatoid Arthritis, Prescription Population, 2000-2008
    • Table 37: MAbs Market, Global, Rheumatoid Arthritis, Prescription Population, 2008-2015
    • Table 38: MAbs Market, Global, Rheumatoid Arthritis, Annual Cost of Therapy ($), 2000-2008
    • Table 39: MAbs Market, Global, Rheumatoid Arthritis, Annual Cost of Therapy ($), 2008-2015
    • Table 40: MAbs Market, Global, Rheumatoid Arthritis, Market Potential ($ bn), 2000-2008
    • Table 41: MAbs Market, Global, Rheumatoid Arthritis, Market Potential ($ bn), 2008-2015
    • Table 42: MAbs Market, Global, Monoclonal Antibody Nomenclature
    • Table 43: MAbs Market, Global, Licensing Agreements for Drugs in the Preclinical Stage,
  • 2008-2009
    • Table 44: MAbs Market, Global, Licensing Agreements for Drugs in the Phase I, 2008-2009
    • Table 45: MAbs Market, Global, Licensing Agreements for Drugs in the Phase II, 2008-2009
    • Table 46: MAbs Market, Global, Licensing Agreements for Drugs in the Phase III, 2008-2009
    • Table 47: MAbs Market, Global, Licensing Agreements for Approved Drugs, 2008-2009
    • Table 48: MAbs Market, Global, Top 5 Companies Sales ($m), 2006-2008
    • Table 49: MAbs Market, Global, Top 10 MAbs ($m), 2006-2008
    • Table 50: MAbs Market, Global, Roche/Genentech Revenue ($ m), 2006-2015
    • Table 51: MAbs Market, Global, Abbott Revenue ($ m), 2006-2015
    • Table 52: MAbs Market, Global, Johnson & Johnson Revenue ($ m), 2006-2015
    • Table 53: MAbs Market, Global, Biogen Idec Revenue ($ m), 2006-2015
    • Table 54: MAbs Market, Global, Merck/Schering Plough Revenues ($ m), 2006-2015
    • Table 55: MAbs Market, Global, AstraZeneca Revenues ($ m), 2006-2015
    • Table 56: MAbs Market, Global, Bristol-Myers Squibb Revenues ($ m), 2006-2015
    • Table 57: MAbs Market, Global, Elan Revenues ($ m), 2006-2015
    • Table 58: MAbs Market, Global, Eli Lilly, Revenues ($ m), 2006-2015
    • Table 59: MAbs Market, Global, Amgen Revenues ($ m), 2006-2015
  • 1.2 List of Figures
    • Figure 1: MAbs Market, Global, Major Factors Influencing the Global MAbs Market, 2008
    • Figure 2: MAbs Market, Global, MAbs Treatment Potential, 2000-15
    • Figure 3: MAbs Market, Global, Annual Cost of Therapy ($), 2000-2015
    • Figure 4: MAbs Market, Global, MAbs Market Potential ($ bn), 2000-2015
    • Figure 5: MAbs Market, Global, Market Segmentation by Disease, 2008 and 2015
    • Figure 6: MAbs Market, Global, MAbs Actual Treatment Population, 2000-2015
    • Figure 7: MAbs Market, Global, Actual Sales ($ bn), 2000-2015
    • Figure 8: MAbs Market, Global, Actual Sales Segmentation ($ bn), 2008 and 2015
    • Figure 9: MAbs Market, Global, Actual Sales Segmentation ($ bn), 2000-2015
    • Figure 10: MAbs Market, Global, Treatment Population Trends, 2000-2015
    • Figure 11: MAbs Market, Global, MAbs Segmented by Origin, 1992-2009
    • Figure 12: MAbs Market, Global, Market Share of Key Indications, 2008
    • Figure 13: MAbs Market, Global, HER2+ Breast Cancer, Prescription Population, 2000-2015
    • Figure 14: MAbs Market, Global, HER2+ Breast Cancer, Annual Cost of Therapy ($), 2000-2015
    • Figure 15: MAbs Market, Global, HER2+ Breast Cancer, Market Potential ($ bn), 2000-2015
    • Figure 16: MAbs Market, Global, Bone Metastasis and Bone Loss, Prescription Population, 2009-2015
    • Figure 17: MAbs Market, Global, Bone Metastasis and Bone Loss, Annual Cost of Therapy ($), 2009-2015
    • Figure 18: MAbs Market, Global, Bone Metastasis and Bone Loss, Market Potential ($ bn), 2009-2015
    • Figure 19: MAbs Market, Global, Multiple Sclerosis, Diseased Population, 2008
    • Figure 20: MAbs Market, Global, RRMS, Prescription Population, 2000-2015
    • Figure 21: MAbs Market, Global, RRMS, Annual Cost of Therapy ($), 2000-2015
    • Figure 22: MAbs Market, Global, RRMS, Market Potential ($ bn), 2000-2015
    • Figure 23: MAbs Market, Global, Metastatic NSCLC, Prescription Population, 2000-2015
    • Figure 24: MAbs Market, Global, Metastatic NSCLC, Annual Cost of Therapy ($), 2000-2015
    • Figure 25: MAbs Market, Global, Metastatic NSCLC, Market Potential ($ bn), 2000-2015
    • Figure 26: MAbs Market, Global, Rheumatoid Arthritis, Prescription Population, 2000-2015
    • Figure 27: MAbs Market, Global, Rheumatoid Arthritis, Annual Cost of Therapy ($), 2000-2015
    • Figure 28: MAbs Market, Global, Rheumatoid Arthritis, Market Potential ($ bn), 2000-2015
    • Figure 29: MAbs Market, Global, Pipeline Segmentation by Disease, 2009
    • Figure 30: MAbs Market, Global, Oncology Pipeline, 2009
    • Figure 31: MAbs Market, Global, Autoimmune Diseases Pipeline, 2009
    • Figure 32: MAbs Market, Global, Respiratory Diseases Pipeline by Phase of Development, 2009
    • Figure 33: MAbs Market, Global, Infectious Diseases Pipeline by Phase of Development, 2009
    • Figure 34: MAbs Market, Global, Organ Transplantation Pipeline by Phase of Development, 2009
    • Figure 35: MAbs Market, Global, Cardiovascular Pipeline by Phase of Development, 2009
    • Figure 36: MAbs Market, Global, Other New Indications in Pipeline, 2009
    • Figure 37: MAbs Market, Global Major M&A Deals, 2008-2009
    • Figure 38: MAbs Market, Global, Major Licensing Agreements by Phase, 2008-2009
    • Figure 39: MAbs Market, Global, Major Licensing Agreements By Geography, 2008-2009
    • Figure 40: MAbs Market, Global, Major Licensing Agreements By Deal Value, 2008-2009
    • Figure 41: MAbs Market, Global, Top Three Companies, 2008
    • Figure 42: MAbs Market, Global, Top 5 Companies Sales Trend, 2006-2008
    • Figure 43: MAbs Market, Global, Key Target Therapies Launched, 1997-2009
    • Figure 44: MAbs Market, Global, Company Market Share Analysis, 2008
    • Figure 45: MAbs Market, Global, Company Benchmarking Analysis, 2008
    • Figure 46: MAbs Market, Global, Top 10 MAbs, 2006-2008
    • Figure 47: MAbs Market, Global, Roche/Genentech Revenue Segmentation, 2008
    • Figure 48: MAbs Market, Global, Roche/Genentech Revenue ($ m), 2006-2015
    • Figure 49: MAbs Market, Global, Roche/Genentech R&D Pipeline by Therapeutic Area, November 2009
    • Figure 50: MAbs Market, Global, Roche/Genentech Pipeline Analysis by Phase, November 2009
    • Figure 51: MAbs Market, Global, Abbott Revenue Segmentation, 2008
    • Figure 52: MAbs Market, Global, Abbott Revenue ($ m), 2006-2015
    • Figure 53: MAbs Market, Global, Abbott Pipeline Analysis by Phase, November 2009
    • Figure 54: MAbs Market, Global, Johnson & Johnson Revenue ($ m), 2006-2015
    • Figure 55: MAbs Market, Global, Johnson & Johnson R&D Pipeline by Therapeutic Area, November 2009
    • Figure 56: MAbs Market, Global, Johnson & Johnson Pipeline Analysis by Phase, November 2009
    • Figure 57: MAbs Market, Global, Biogen Idec Revenue Segmentation, 2008
    • Figure 58: MAbs Market, Global, Biogen Idec Revenue ($ m), 2006-2015
    • Figure 59: MAbs Market, Global, Biogen Idec R&D Pipeline by Therapeutic Area, November 2009
    • Figure 60: MAbs Market, Global, Biogen Idec Pipeline Analysis by Phase, November 2009
    • Figure 61: MAbs Market, Global, Merck/Schering Plough Revenues ($ m), 2006-2015
    • Figure 62: MAbs Market, Global, Merck/Schering-Plough R&D Pipeline by Therapeutic Area, November 2009
    • Figure 63: MAbs Market, Global, Merck/Schering-Plough Pipeline Analysis by Phase, November 2009
    • Figure 64: MAbs Market, Global, AstraZeneca Revenues ($ m), 2006-2015
    • Figure 65: MAbs Market, Global, AstraZeneca R&D Pipeline by Therapeutic Area, November 2009
    • Figure 66: MAbs Market, Global, AstraZeneca Pipeline Analysis by Phase, November 2009
    • Figure 67: MAbs Market, Global, Bristol-Myers Squibb Revenues ($ m), 2006-2015
    • Figure 68: MAbs Market, Global, Bristol-Myers Squibb R&D Pipeline by Phase, November 2009
    • Figure 69: MAbs Market, Global, Elan Revenues ($ m), 2006-2015
    • Figure 70: MAbs Market, Global, Elan R&D Pipeline by Therapeutic Area, November 2009
    • Figure 71: MAbs Market, Global, Elan Pipeline Analysis by Phase, November 2009
    • Figure 72: MAbs Market, Global, Eli Lilly, Revenues ($ m), 2006-2015
    • Figure 73: MAbs Market, Global, Eli Lilly R&D Pipeline by Therapeutic Area, November 2009
    • Figure 74: MAbs Market, Global, Eli Lilly Pipeline Analysis by Phase, November 2009
    • Figure 75: MAbs Market, Global, Amgen Revenues ($ m), 2006-2015
    • Figure 76: MAbs Market, Global, Amgen R&D Pipeline by Therapeutic Area, November 2009
    • Figure 77: MAbs Market, Global, Amgen Pipeline Analysis by Phase, November 2009
    • Figure 78: GBI Research Methodology
    • Figure 79: GBI Research Market Forecasting Model